Amendments to the Claims:

This list of claims will replace all prior versions, and listings, of claims in U.S. Patent No. 6,468,542:

Listing of Claims:

Claim 1 (original): A pharmaceutical preparation comprising

activated sporoderm-broken ganoderma spores and optionally a pharmaceutically acceptable carrier;

wherein said activated sporoderm-broken ganoderma spores are prepared by:

soaking ganoderma spores in a solution which is selected from the group consisting of water, saline, and a nutritional solution to cause the spores to germinate;

placing said germination-treated ganoderma spores in a culture box at a relative humidity of 65-98% and temperature of 18-48°C to cause the germinated ganoderma spores to activate; and

treating the germination activated ganoderma spores to break the spores to produce activated sporoderm-broken ganoderma spores.

Claim 2 (original): The pharmaceutical preparation according to claim 1, wherein said ganoderma spores are soaked in the solution for 30 minutes to 8 hours at no more than 50°C.

Claim 3 (original): The pharmaceutical preparation according to claim 1, wherein said nutritional solution is at least one selected from the group consisting of coconut juice, malt extract, ganoderma sporocarp extract, ganoderma capillitia extract, culture solution containing biotin, and culture solution containing monobasic potassium phosphate and magnesium sulfate.

Claim 4 (original): The pharmaceutical preparation according to claim 2, wherein said ganoderma spores are soaked in the solution for 2 to 4 hours.

Claim 5 (original): The pharmaceutical preparation according to claim 2, wherein said ganoderma spores are soaked in the solution at 20 to 43°C.

Claim 6 (original): The pharmaceutical preparation according to claim 1, wherein said solution is 0.1-5 times the weight of said spores.

Claim 7 (original): The pharmaceutical preparation according to claim 1, wherein the spores are broken by treating the germination activated ganoderma spores with an enzyme with cell wall dissolving property.

Claim 8 (original): The pharmaceutical preparation according to claim 7, wherein enzyme is chitinase or cellulase.

Claim 9 (original): The pharmaceutical preparation according to claim 1, further comprising treating the germination activated ganoderma spores with a mechanical force.

Claim 10 (original): The pharmaceutical preparation according to claim 9, wherein said mechanical force is at least one selected from the group consisting of micronization, roll pressing, grinding, ultrasond, and super high pressure microstream treatment.

Please add new claims 11-18 as follows:

Claim 11 (new): The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation reduces free radicals in a tumor tissue.

Claim 12 (new): The pharmaceutical preparation according to claim 11, wherein said reduction of free radicals is observed by a reduction of malondialdehye in said tumor tissue.

Claim 13 (new): The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation reduces weight of solid tumor in a mammal.

Claim 14 (new): The pharmaceutical preparation according to claim 13, wherein said solid tumor is a sarcoma.

Claim 15 (new): The pharmaceutical preparation according to claim 14, wherein said solid tumor is a reticulocyte sarcoma.

Claim 16 (new): The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation has therapeutic effect on hepatitis B in a human.

Claim 17 (new): The pharmaceutical preparation according to claim 16, wherein said human is an asymptomatic carrier of hepatitis B.

Claim 18 (new): The pharmaceutical preparation according to claim 16, wherein said human has chronic hepatitis.

Claim 19 (new): The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation reduces the size of hepatoma in a human.

Claim 20 (new): The pharmaceutical preparation according to claim 1, wherein said pharmaceutical preparation provides moderate glucose control in a human.